The value of CAR T-cell therapy in refractory or relapsed diffuse large B cell lymphoma (RR DLBCL) has been further boosted by a study showing the salvage therapy also leads to better physical and social function in addition to its impressive survival outcomes in patients with advanced disease. In a post hoc analysis of patient-reported ...
After CAR T-cell therapy, quality of life is good for people with RR DLBCL
By Sunalie Silva
12 Mar 2020